MétaCan
Menu
Back to cohort
Record W2337828519 · doi:10.1186/s12888-016-0785-x

Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort

2016· article· en· W2337828519 on OpenAlexafffundabout
Raymond W. Lam, Roumen Milev, Susan Rotzinger, Ana C. Andreazza, Pierre Blier, Colleen A. Brenner, Zafiris J. Daskalakis, Moyez Dharsee, Jonathan Downar, Kenneth Evans, Faranak Farzan, Jane A. Foster, Benício N. Frey, Joseph Geraci, Peter Giacobbe, Harriet Feilotter, Geoffrey B. Hall, Kate L. Harkness, Stefanie Hassel, Zahinoor Ismail, Francesco Leri, Mario Liotti, Glenda MacQueen, Mary Pat McAndrews, Luciano Minuzzi, Daniel J. Müller, Sagar V. Parikh, Franca Placenza, Lena C. Quilty, Arun Ravindran, Tim V. Salomons, Cláudio N. Soares, Stephen C. Strother, Gustavo Turecki, Anthony L. Vaccarino, Fidel Vila‐Rodriguez, Sidney H. Kennedy

Bibliographic record

VenueBMC Psychiatry · 2016
Typearticle
Languageen
FieldMedicine
TopicTreatment of Major Depression
Canadian institutionsDouglas Mental Health University InstituteBaycrest HospitalSt. Michael's HospitalUniversity of CalgaryMcMaster UniversityIndoc ResearchSt. Joseph’s Healthcare HamiltonRoyal Ottawa Mental Health CentreMcGill UniversitySimon Fraser UniversityUniversity of OttawaUniversity of TorontoUniversity Health NetworkQueen's UniversityUniversity of British ColumbiaUniversity of GuelphCentre for Addiction and Mental HealthVancouver Coastal Health
FundersDaiichi Sankyo EuropeServierUniversity of TorontoH. Lundbeck A/SJ.P. Bickell FoundationNational Institutes of HealthCanadian Network for Mood and Anxiety TreatmentsCentre for Addiction and Mental HealthCanadian Institutes of Health ResearchCentre for Addiction and Mental Health FoundationSunovionOntario Brain InstitutePfizerGovernment of OntarioBrainsWayNational Alliance for Research on Schizophrenia and DepressionEli Lilly and CompanyBristol-Myers SquibbAstraZenecaHamilton Health Sciences FoundationCampbell InstituteHamilton Health Sciences
KeywordsMajor depressive disorderAntidepressantBiomarkerMedicineAripiprazoleNeurocognitiveClinical trialNeuroimagingEscitalopramPsychiatryOncologyDepression (economics)BioinformaticsClinical psychologyPsychologyInternal medicineMoodCognitionSchizophrenia (object-oriented programming)Biology

Abstract

fetched live from OpenAlex

BACKGROUND: Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers ("biomarkers") of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological, molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in MDD. METHODS: CAN-BIND-1 is a multisite initiative involving 6 academic health centres working collaboratively with other universities and research centres. In the 16-week protocol, patients with MDD are treated with a first-line antidepressant (escitalopram 10-20 mg/d) that, if clinically warranted after eight weeks, is augmented with an evidence-based, add-on medication (aripiprazole 2-10 mg/d). Comprehensive datasets are obtained using clinical rating scales; behavioural, dimensional, and functioning/quality of life measures; neurocognitive testing; genomic, genetic, and proteomic profiling from blood samples; combined structural and functional magnetic resonance imaging; and electroencephalography. De-identified data from all sites are aggregated within a secure neuroinformatics platform for data integration, management, storage, and analyses. Statistical analyses will include multivariate and machine-learning techniques to identify predictors, moderators, and mediators of treatment response. DISCUSSION: From June 2013 to February 2015, a cohort of 134 participants (85 outpatients with MDD and 49 healthy participants) has been evaluated at baseline. The clinical characteristics of this cohort are similar to other studies of MDD. Recruitment at all sites is ongoing to a target sample of 290 participants. CAN-BIND will identify biomarkers of treatment response in MDD through extensive clinical, molecular, and imaging assessments, in order to improve treatment practice and clinical outcomes. It will also create an innovative, robust platform and database for future research. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01655706 . Registered July 27, 2012.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.020
metaresearch head score (Gemma)0.026
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.653
Threshold uncertainty score0.690

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0200.026
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0020.004
Science and technology studies0.0060.002
Scholarly communication0.0020.001
Open science0.0030.002
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0180.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.308
Teacher spread0.285 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations148
Published2016
Admission routes3
Has abstractyes

Explore more

Same venueBMC PsychiatrySame topicTreatment of Major DepressionFrench-language works237,207